Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XF-73 nasal gel for S. aureus decolonisation
NCT02282605Phase 2Completed
- Sponsor
- Destiny Pharma
- Start
- Sep 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of exeporfinium chloride in Staphylococcus aureus nasal carriage, sponsored by Destiny Pharma. Started Sep 2014; status: completed.
02
Drugs
exeporfinium chloride
03
Conditions
Staphylococcus aureus nasal carriage
Beyond the preview
Go deeper on NCT02282605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282605.